Phase II study on the combination of irinotecan plus cisplatin as a second-line therapy in patients with advanced or recurrent gastric cancer

Abstract

A pilot phase II study was conducted to evaluate the efficacy and safety of the combined administration of irinotecan (CPT-11) plus cisplatin (CDDP) as a second-line therapy for advanced or recurrent gastric cancer. Between November, 2006 and May, 2009, 18 patients were enrolled in this study. The patients were required to have received prior chemotherapy with S-1 (n=17), an orally administered 5-fluorouracil (5-FU) prodrug, or S-1 plus CDDP (n=1). CPT-11 and CDDP were administered at a dose of 60 and 30 mg/m2, respectively, on days 1 and 15 of a 4-week treatment cycle. The regimen was repeated until the occurrence of unacceptable toxicity, disease progression, or patient refusal. The primary endpoint of this study was the response rate (RR). In the second-line setting, 2 cases of complete response (CR), 1 of partial response (PR) and 7 of stable disease (SD) were identified. The RR was 16.7% and the disease control rate (DCR) was 55.6%. The median survival time (MST) and progression-free survival (PFS) was 282 and 111 days, respectively. As regards hematological toxicity, the major adverse effect during the second-line of chemotherapy was grade 3–4 leukopenia (22.2%). In addition, with regard to non-hematological toxicities, the major adverse effect during the second-line chemotherapy was grade 3–4 loss of appetite (11.1%). There was no mortality attributable to the adverse effects of the drugs. Findings of the present study suggested that CPT-11 and CDDP combination therapy in a second-line setting is an effective regimen in the treatment of advanced gastric cancer.

The role of maintenance therapy in the treatment of elderly non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials

“… 3 Currently, platinum-based doublet chemotherapy is the standard of care for first-line therapy. 4 – 6 However, outcomes of advanced NSCLC is disappointing, with 5-year overall survival (OS) <5%. Clearly, novel anti-cancer agents or treatment strategies are needed to improve the survival of these patients.…”

Efficacy and Toxicity of Second-Course Ophthalmic Artery Chemosurgery for Retinoblastoma

“…The answer is different depending on the tumor type and the regimen used. Some tumors such as gastric cancer and other solid tumors have responded unsatisfactorily to second-line treatment 5 , while other tumors (or the same tumors subjected to different regimens) have shown promise 6,7 . This study will review the cases that required second course OAC and determine the response and associated burden of ocular and systemic toxicity.…”

RPL13A as a reference gene for normalizing mRNA transcription of ovarian cancer cells with paclitaxel and 10-hydroxycamptothecin treatments

“…PTX is also able to directly bind to Bcl-2 and induce apoptosis (11). Camptothecin (CPT), a chemotherapeutic drug, has been reported to be efficient at inhibiting the growth of ovarian, hepatic, gastric, colorectal and breast cancer (12)(13)(14)(15)(16). CPT and its derivatives are able to inhibit the replication and transcription of DNA and mitosis by acting on type-I DNA topoisomerase (17,18).…”